论文部分内容阅读
目的:探讨达立通与兰索拉唑联合治疗反流性食管炎的临床疗效。方法:66例反流性食管炎患者随机分为A组与B组,各33例。A组予以兰索拉唑治疗,B组予以达立通颗粒联合兰索拉唑治疗,对照两组的临床疗效。结果:B组的治疗总有效率为93.94%,显著高于A组的75.76%(P<0.05);两组均未见明显不良反应。结论:达立通与兰索拉唑联合治疗反流性食管炎可提高临床疗效,不增加药物不良反应,值得在临床中推广应用。
Objective: To investigate the clinical efficacy of Dalitong combined with lansoprazole in the treatment of reflux esophagitis. Methods: Sixty-six patients with reflux esophagitis were randomly divided into group A and group B, with 33 cases in each group. Group A was treated with lansoprazole, group B was treated with daclopride particles combined with lansoprazole, the control group, the clinical efficacy. Results: The total effective rate in group B was 93.94%, which was significantly higher than that in group A (75.76%, P <0.05). No obvious adverse reactions were observed in both groups. Conclusion: The combination of daclopidine and lansoprazole in the treatment of reflux esophagitis can improve the clinical curative effect without increasing adverse drug reactions, which is worth popularizing in clinic.